Description
General description
CpGenome Universal Unmethylated DNA Set provides 2 separate genomic DNA controls for gene methylation studies. This product is intended for use with the CpGenome DNA Modification Kit (S7820) and can be subsequently used as an unmethylated DNA control for gene methylation studies.
Materials Provided:
Universal Unmethylated DNA Vial A contains 5 micrograms (50μL) of human genomic DNA at a concentration of 0.1 μg/μL. Universal Unmethylated DNA Vial B contains 5 micrograms (50μL), of genomic DNA isolated from a primary human fetal cell line at a concentration of 0.1 μg/μL. Note: The DNA must first be bisulfite modified using (S7820) to use a specific primer set for the unmethylated form of the gene of interest.
Validation:
Methylation-specific PCR (MSP) was performed on the DNA following bisulfite modification. Various primer sets from the CpG WIZ product line were used in the assay. DNA from Vial A has been validated with primers from several CpG WIZ amplification kits. Vial B DNA is also unmethylated at several promoters assayed with the CpG WIZ kits and is supplied as an alternative source of DNA for promoters that may be partially methylated in Vial A DNA.
CpG Genome and CpG WIZ Methylation Products apply technologies exclusively licensed from The Johns Hopkins University School of Medicine. Methylation-specific PCR (MSP) technology is covered by U.S. Patent # 5,786,146.
Methylation of cytosines located 5′ to guanosine is known to have a profound effect on the expression of many eukaryotic genes. In normal cells methylation occurs predominantly in CG-poor regions, while CG-rich areas, called CpG-islands remain unmethylated. The exceptions are the extensive methylation of CpG islands associated with transcriptional inactivation of regulatory regions of imprinted genes and genes on the inactive X-chromosome of females. Aberrant methylation of normally unmethylated CpG islands has been documented as a relatively frequent event in immortalized and transformed cells and has been associated with transcriptional inactivation of defined tumor suppresser genes in human cancers. Hundreds of CpG islands are now known to exhibit the characteristic of hypermethylation in tumors.
Several methods have been developed to determine the methylation status of cytosine. These include digestion with methylation sensitive restriction enzymes as in restriction landmark genomic scanning, oligonucleotide arrays, genomic DNA sequencing and methylation specific PCR (MSP). Some techniques are more useful for discovery while others are better used for monitoring of known methylated cytosines. Genomic DNA sequencing, although time consuming and labor intensive, offers a more universal detection method. MSP is now an established technology for the monitoring of abnormal gene methylation in selected gene sequences. Utilizing small amounts of DNA, this procedure offers sensitive and specific detection of 5-methylcytosine in promoters. It is being exploited to define tumor suppresser gene function, and to provide a new strategy for early tumor detection.
The initial step of both genomic sequencing and MSP is to perform a bisulfite modification of the DNA sample. MSP then involves PCR amplification with specific primers designed to distinguish methylated from unmethylated DNA.
Packaging
2 x 5 μg
Physical form
Liquid in TE (10mM Tris-HCL, 0.1mM EDTA) with no preservatives.
Preparation Note
Recommended Storage: -15°C to -25°C, in aliquots, protected from freeze-thaws for up to two years from date of receipt. Do not freeze and thaw the same -20°C aliquot more than 3X for best results. Multiple freeze thaws can fragment DNA. Storage at -70°C can be used for longer term storage if necessary; minimize multiple freeze thaws for best results.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
